Healthpeak Properties, Inc. (DOC) Stock Price & Growth Analysis

Quote Panel

Updated September 21, 2025

1W 1.76 % 1M 4.06 % 3M 6.82 % 1Y -13.25 %

Key Metrics

Market Cap
12.84B
Shares Outstanding
694.92M
Share in Float
692.05M
Dividende
1.21502

Earning Date
23 Oct 2025
Price Target
18.47
Average Volume
7.25M
Beta
1.042

Range
16.63-23.26
Industry
REIT - Healthcare Facilities
Website
https://www.healthpeak.com
Sector
Real Estate

Quote Panel

Updated September 21, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

10.09x

P/E Ratio

4.59x

P/S Ratio

1.62x

P/B Ratio

1.2

Debt/Equity

5.9%

Net Margin

$0.2

EPS

How DOC compares to sector?

P/E Ratio

Fundamentals

Relative Strength

DOC

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

DOC

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$3B

298%

2026-Revenue

$0.29

528%

2026-EPS

$2B

316%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

21.00(13.70%)

Number of analyst

Last analyst upgrade/downgrade

Raymond James

upgrade

Previous: Not converted

2025-09-15

Now: Outperform

Deutsche Bank

upgrade

Previous: Not converted

2024-10-21

Now: Buy

Wedbush

upgrade

Previous: Not converted

2024-05-03

Now: Outperform

Exane BNP Paribas

upgrade

Previous: Not converted

2024-04-26

Now: Outperform

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q3.23

+5%

0.45
vs 0.43

Q4.23

+5%

0.46
vs 0.44

Q1.24

+7%

0.45
vs 0.42

Q2.24

N/A

0.45
vs 0.45

Q3.24

N/A

0.45
vs 0.45

Q4.24

N/A

0.46
vs 0.46

Q1.25

+2%

0.46
vs 0.45

Q2.25

+2%

0.46
vs 0.45

Q3.25

-87%

0.06
vs 0.45

Q4.25

-87%

0.06
vs 0.46

Sales Growth

YoY

Current

Estimates

Q3.23

+7%

556.2M vs 520.4M

Q4.23

+6%

553.7M vs 524.5M

Q1.24

+15%

606.6M vs 525.7M

Q2.24

+28%

695.5M vs 545.4M

Q3.24

+26%

700.4M vs 556.2M

Q4.24

+26%

698M vs 553.7M

Q1.25

+16%

702.9M vs 606.6M

Q2.25

694.3M vs 695.5M

Q3.25

-5%

663.9M vs 700.4M

Q4.25

-4%

670M vs 698M

Return on Equity

QoQ

Q1.23

+4%

0.04
vs 0

Q2.23

+2%

0.02
vs 0.04

Q3.23

+1%

0.01
vs 0.02

Q4.23

+1%

0.01
vs 0.01

Q1.24

+0%

0
vs 0.01

Q2.24

+2%

0.02
vs 0

Q3.24

+1%

0.01
vs 0.02

Q4.24

+0%

0
vs 0.01

Q1.25

+1%

0.01
vs 0

Q2.25

+0%

0
vs 0.01

Institutionnal Ownership

QoQ

Q1.23

363

363
vs 357

Q2.23

356

356
vs 363

-2%

Q3.23

363

363
vs 356

Q4.23

351

351
vs 363

-3%

Q1.24

691

691
vs 351

97%

Q2.24

711

711
vs 691

Q3.24

742

742
vs 711

Q4.24

764

764
vs 742

Q1.25

758

758
vs 764

-1%

Q2.25

713

713
vs 758

-6%

Earnings Growth

YoY

Current

Estimates

Q3.23

+5%

0.45
vs 0.43

Q4.23

+5%

0.46
vs 0.44

Q1.24

+7%

0.45
vs 0.42

Q2.24

N/A

0.45
vs 0.45

Q3.24

N/A

0.45
vs 0.45

Q4.24

N/A

0.46
vs 0.46

Q1.25

+2%

0.46
vs 0.45

Q2.25

+2%

0.46
vs 0.45

Q3.25

-87%

0.06
vs 0.45

Q4.25

-87%

0.06
vs 0.46

Sales Growth

YoY

Current

Estimates

Q3.23

+7%

556.2M vs 520.4M

Q4.23

+6%

553.7M vs 524.5M

Q1.24

+15%

606.6M vs 525.7M

Q2.24

+28%

695.5M vs 545.4M

Q3.24

+26%

700.4M vs 556.2M

Q4.24

+26%

698M vs 553.7M

Q1.25

+16%

702.9M vs 606.6M

Q2.25

694.3M vs 695.5M

Q3.25

-5%

663.9M vs 700.4M

Q4.25

-4%

670M vs 698M

Return on Equity

QoQ

Q1.23

+4%

0.04
vs 0

Q2.23

+2%

0.02
vs 0.04

Q3.23

+1%

0.01
vs 0.02

Q4.23

+1%

0.01
vs 0.01

Q1.24

+0%

0
vs 0.01

Q2.24

+2%

0.02
vs 0

Q3.24

+1%

0.01
vs 0.02

Q4.24

+0%

0
vs 0.01

Q1.25

+1%

0.01
vs 0

Q2.25

+0%

0
vs 0.01

Institutionnal Ownership

QoQ

Q1.23

363

363
vs 357

Q2.23

356

356
vs 363

-2%

Q3.23

363

363
vs 356

Q4.23

351

351
vs 363

-3%

Q1.24

691

691
vs 351

97%

Q2.24

711

711
vs 691

Q3.24

742

742
vs 711

Q4.24

764

764
vs 742

Q1.25

758

758
vs 764

-1%

Q2.25

713

713
vs 758

-6%

Earnings Growth

Forecast

$3B

298%

2026-Revenue

$0.29

528%

2026-EPS

$2B

316%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

21.00(13.70%)

Number of analyst

Last analyst upgrade/downgrade

Raymond James

upgrade

Previous: Not converted

2025-09-15

Now: Outperform

Deutsche Bank

upgrade

Previous: Not converted

2024-10-21

Now: Buy

Wedbush

upgrade

Previous: Not converted

2024-05-03

Now: Outperform

Exane BNP Paribas

upgrade

Previous: Not converted

2024-04-26

Now: Outperform

Company Description

18.47USD

10.09x

4.59x

1.62x

1.2

5.9%

$0.2

$3B

$0.29

$2B

Earnings Growth

Latest News

Latest News

Latest News

Earnings Growth

$3B

$0.29

$2B

Company Description

18.47USD

10.09x

4.59x

1.62x

1.2

5.9%

$0.2